Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 53, Issue 12

Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis No Access

Abstract

is the causative agent of melioidosis, which is a major cause of morbidity and mortality in endemic regions. Currently there is no human vaccine against melioidosis. In this study, LPS or capsular polysaccharide was used to immunize BALB/c mice. The different polysaccharide antigens induced antibody responses. Mice vaccinated with LPS developed predominantly IgM and IgG3 responses. Contrastingly, mice vaccinated with capsular polysaccharide developed a predominantly IgG2b response. After immunization, mice were challenged by the intra-peritoneal route and an increased mean time to death was observed compared with unvaccinated controls. Immunization with LPS provided an optimal protective response. Mice challenged by the aerosol route showed a small increase in the mean time to death compared with the unvaccinated controls. The passive transfer of antigen from immunized into naïve mice provided protection against a subsequent challenge. This study is the first time antigens protective by active immunization have been identified and suggests that polysaccharides have potential as vaccine candidates against melioidosis.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45766-0
2004-12-01
2025-11-07

Metrics

Loading full text...

Full text loading...

References

  1. Anuntagool N., Intachote P., Wuthiekanun V., White N. J., Sirisinha S. 1998; Lipopolysaccharide from nonvirulent Ara+ Burkholderia pseudomallei isolates is immunologically indistinguishable from lipopolysaccharide from virulent Ara− clinical isolates. Clin Diagn Lab Immunol 5:225–229
     [Google Scholar]
  2. Ashdown L. R. 1992; Rapid differentiation of Pseudomonas pseudomallei from Pseudomonas cepacia. Lett Appl Microbiol 14:203–205 [CrossRef]
     [Google Scholar]
  3. Atkins T., Prior R., Mack K., Russel P., Nelson M., Prior J., Oyston P. C., Dougan G., Titball R. W. 2002; Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol 51:539–547
     [Google Scholar]
  4. Brett P. J., Woods D. E. 1996; Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun 64:2824–2828
     [Google Scholar]
  5. Bryan L. E., Wong S., Woods D. E., Dance D. A. B., Chaowagul W. 1994; Passive protection of the diabetic rat with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can J Infect Dis 5:170–178
     [Google Scholar]
  6. Chaowagul W. 2000; Recent advances in the treatment of severe melioidosis. Acta Trop 74:133–137 [CrossRef]
     [Google Scholar]
  7. Chaowagul W., White N. J., Dance D. A. B., Wattanagoon Y., Naigowit P., Davis T. M. E., Looareesuwan S., Pitakwatchara N. 1989; Melioidosis : a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 159:890–899 [CrossRef]
     [Google Scholar]
  8. Chart H. 1994; LPS: isolation and characterisation. In Methods in Practical Laboratory Bacteriology pp 11–20 Edited by Chart H. Boca Raton, London, Tokyo: CRC Press;
     [Google Scholar]
  9. Charuchaimontri C., Suputtamongkol Y., Nilakul C., Chaowagul W., Chetchotisakd P., Lertpatanasuwan N., Intaranongpai S., Brett P. E., Woods D. E. 1999; Anti-lipopolysaccharide II: an antibody protective against fatal melioidosis. Clin Infect Dis 29:813–818 [CrossRef]
     [Google Scholar]
  10. Dance D. A. B. 2002; Melioidosis. Curr Opin Infect Dis 15:127–132 [CrossRef]
     [Google Scholar]
  11. DeShazer D., Brett P. J., Woods D. E. 1998; The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 30:1081–1100 [CrossRef]
     [Google Scholar]
  12. Harley V. S., Dance D. A. B., Drasar B. S., Tavey G. 1998; Effects of Burkholderia pseudomallei and other Burkholderia species on eukaryotic cells in tissue culture. Microbios 96:71–93
     [Google Scholar]
  13. Ho M., Schollaardt T., Smith M. D., Perry M. B., Brett P. J., Chaowagul W., Bryan L. E. 1997; Specificity and functional activity of anti- Burkholderia pseudomallei polysaccharide antibody. Infect Immun 65:3648–3653
     [Google Scholar]
  14. Johnson K. G., Perry M. B. 1975; Improved techniques for the preparation of bacterial polysaccharides. Can J Microbiol 22:29–34
     [Google Scholar]
  15. Jones A. L., Beveridge T. J., Woods D. E. 1996; Intracellular survival of Burkholderia pseudomallei. Infect Immun 64:782–790
     [Google Scholar]
  16. Jones S. M., Ellis J. F., Russell P., Griffin K. F., Oyston P. C. 2002; Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 52:1055–1062
     [Google Scholar]
  17. Knirel Y. A., Paramonov N. A., Shashkov A. S., Kochetkov N. K., Yarullin R. G., Farber S. M., Efremenko V. I. 1992; Structure of the polysaccharide chains of Pseudomonas pseudomallei lipopolysaccharide. Carbohydr Res 233:185–193 [CrossRef]
     [Google Scholar]
  18. Kourounakis L. H., Moller E. 1984; Adjuvants influence the immunoglobin subclass distribution of immune responses in vivo . Scand J Immunol 19:219–225
     [Google Scholar]
  19. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [CrossRef]
     [Google Scholar]
  20. Lee C. J., Banks S. D., Li J. P. 1991; Virulence, immunity and vaccine related to Streptococcus pneumoniae . Crit Rev Microbiol 18:89–111 [CrossRef]
     [Google Scholar]
  21. Makela P. H. 2003; Conjugate vaccines – a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 34:249–253
     [Google Scholar]
  22. Masihi K. N., Lange W., Brehmer W., Ribi E. 1986; Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int J Immunopharmacol 8:339–345 [CrossRef]
     [Google Scholar]
  23. Perry M. B., MacLean L. L., Schollaardt T., Bryan L. E., Ho M. 1995; Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei . Infect Immun 63:3348–3352
     [Google Scholar]
  24. Pitt T. L., Aucken H., Dance D. A. B. 1992; Homogeneity of lipopolysaccharide antigens in Pseudomonas pseudomallei. J Infect 25:139–146
     [Google Scholar]
  25. Reckseidler S. L., DeShazer D., Sokol P. A., Woods D. E. 2001; Detection of bacterial virulence genes by subtractive hybridisation: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun 69:34–44 [CrossRef]
     [Google Scholar]
  26. Russell P., Eley S. M., Green M. & 8 other authors; 1998; Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J Antimicrob Chemother 41:301–305 [CrossRef]
     [Google Scholar]
  27. Stein K. E. 1992; Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 165 (Suppl. 1):S49–S52 [CrossRef]
     [Google Scholar]
  28. Steinmetz I., Rohde M., Brenneke B. 1995; Purification and characterisation of an exopolysaccharide of Burkholderia ( Pseudomonas ) pseudomallei . Infect Immun 63:3959–3965
     [Google Scholar]
  29. van de Wijgert J. H., Verheul A. F., Snippe H., Check I. J., Hunter R. L. 1991; Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution. Infect Immun 59:2750–2757
     [Google Scholar]
  30. Westphal O., Jann K. 1965; Bacterial lipopolysaccharides.Extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 5:83–91
     [Google Scholar]
  31. White N. J., Dance D. A. B., Chaowagul W. 1989; Halving the mortality of severe melioidosis by ceftazidime. Lancet 2:697–701
     [Google Scholar]
  32. Woods D. E., Jones A. L., Hill P. J. 1993; Interaction of insulin with Pseudomonas pseudomallei . Infect Immun 61:1914–1919
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.45766-0
Loading
Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis
J. Med. Microbiol. 53, 1177 (2004); https://doi.org/10.1099/jmm.0.45766-0
/content/journal/jmm/10.1099/jmm.0.45766-0
/content/journal/jmm/10.1099/jmm.0.45766-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error